Portfolio and Projects
Below, you will find a selection of published research work and side projects that I have completed to showcase my research, epidemiologic and statistical technique.
About
My Research Portfolio
Through my research, I have contributed to studies that deepen our understanding of cancer care, patient outcomes, and healthcare delivery. My work has been shared through peer-reviewed publications and conference presentations, helping translate complex health data into evidence that can inform clinical practice and policy. I am motivated by the opportunity to generate research that extends beyond academia and contributes to better health outcomes at the population level.
My research has notably taken me to the European Society for Medical Oncology Congress 2025 and the Canadian Association of Medical Oncologists 2025 Annual Scientific Meeting. There, I was able to disseminate the results from my graduate research to pharmaceutical stakeholders, clinicians, academics and government decision-makers.
Below are a curated group of deliverables to showcase the amazing work I had done in pursuit of my Master’s in Epidemiology and Biostatistics. Click any image to see to the associated deliverable. From left to right: (1) Thesis dissertation; (2) Abstract published in the Annals of Oncology; (3) Poster presentation submitted to the ESMO Congress 2025
Side Projects
Click on any button below to be taken to the associated side project. Each project will presented differently, with a focus on a distinct statistical and epidemiological topic.
Project One
Real-world impacts of Imlunestrant
Investigating progression free survival, through Kaplan-Meier and multivariable Cox models, and safety endpoints in patients with ER+/HER2- metastatic breast cancer receiving imlunestrant or standard ET
Project Two
Determining genetic feature importance
Comparing the performance of penalized logistic regression, random forest, extreme gradient boosted, and support vector machine learning models in determining genetic feature importance for a hypothetical disease
Project Three
Cost-Effectiveness of Finerenone
Comparing the cost-effectiveness of Finerenone (Kerendia) to standard therapy for patients with HF with a mildly reduced or preserved ejection fraction (a left ventricular ejection fraction ≥ 40%)
